{
    "General": {
        "Code": "5HZ1",
        "Type": "Common Stock",
        "Name": "HANGZHOU TIGERMED CO. H 1",
        "Exchange": "F",
        "CurrencyCode": "EUR",
        "CurrencyName": "Euro",
        "CurrencySymbol": "\u20ac",
        "CountryName": "Germany",
        "CountryISO": "DE",
        "OpenFigi": null,
        "ISIN": "CNE1000040M1",
        "LEI": null,
        "PrimaryTicker": null,
        "CIK": null,
        "EmployerIdNumber": null,
        "FiscalYearEnd": "December",
        "IPODate": null,
        "InternationalDomestic": null,
        "Sector": "Healthcare",
        "Industry": "Diagnostics & Research",
        "GicSector": "Health Care",
        "GicGroup": "Pharmaceuticals, Biotechnology & Life Sciences",
        "GicIndustry": "Biotechnology",
        "GicSubIndustry": "Biotechnology",
        "Description": "Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.",
        "Address": null,
        "AddressData": null,
        "Listings": {},
        "Officers": {},
        "Phone": null,
        "WebURL": null,
        "LogoURL": "",
        "FullTimeEmployees": 9233,
        "UpdatedAt": "2023-08-31"
    },
    "Highlights": {
        "MarketCapitalization": 6933881344,
        "MarketCapitalizationMln": 6933.8813,
        "EBITDA": 1913519104,
        "PERatio": 15.5,
        "PEGRatio": null,
        "WallStreetTargetPrice": null,
        "BookValue": 23.761,
        "DividendShare": 0.55,
        "DividendYield": 0.0146,
        "EarningsShare": 0.32,
        "EPSEstimateCurrentYear": 0,
        "EPSEstimateNextYear": 0,
        "EPSEstimateNextQuarter": 0,
        "EPSEstimateCurrentQuarter": 0,
        "MostRecentQuarter": "2023-06-30",
        "ProfitMargin": 0.3059,
        "OperatingMarginTTM": 0.2418,
        "ReturnOnAssetsTTM": 0.0393,
        "ReturnOnEquityTTM": 0.1039,
        "RevenueTTM": 7202112512,
        "RevenuePerShareTTM": 8.334,
        "QuarterlyRevenueGrowthYOY": 0.073,
        "GrossProfitTTM": 2808463884,
        "DilutedEpsTTM": 0.32,
        "QuarterlyEarningsGrowthYOY": 0.217
    },
    "Valuation": {
        "TrailingPE": 15.5,
        "ForwardPE": 0,
        "PriceSalesTTM": 0,
        "PriceBookMRQ": 0,
        "EnterpriseValue": 2762137344,
        "EnterpriseValueRevenue": 0,
        "EnterpriseValueEbitda": 0
    },
    "SharesStats": {
        "SharesOutstanding": 123125000,
        "SharesFloat": 626945734,
        "PercentInsiders": 0,
        "PercentInstitutions": 79.286,
        "SharesShort": null,
        "SharesShortPriorMonth": null,
        "ShortRatio": null,
        "ShortPercentOutstanding": null,
        "ShortPercentFloat": null
    },
    "Technicals": {
        "Beta": 0.8169,
        "52WeekHigh": 12.3538,
        "52WeekLow": 4.76,
        "50DayMA": 5.237,
        "200DayMA": 8.2178,
        "SharesShort": 0,
        "SharesShortPriorMonth": 0,
        "ShortRatio": 0,
        "ShortPercent": 0
    },
    "SplitsDividends": {
        "ForwardAnnualDividendRate": 0.07,
        "ForwardAnnualDividendYield": 0.0146,
        "PayoutRatio": 0.2182,
        "DividendDate": null,
        "ExDividendDate": "2023-05-25",
        "LastSplitFactor": null,
        "LastSplitDate": null,
        "NumberDividendsByYear": {
            "0": {
                "Year": 2022,
                "Count": 1
            },
            "1": {
                "Year": 2023,
                "Count": 1
            }
        }
    },
    "Holders": null,
    "InsiderTransactions": {},
    "outstandingShares": {
        "annual": {},
        "quarterly": {}
    },
    "Earnings": {
        "History": {},
        "Trend": {},
        "Annual": {}
    },
    "Financials": {
        "Balance_Sheet": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Cash_Flow": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        },
        "Income_Statement": {
            "currency_symbol": null,
            "quarterly": {},
            "yearly": {}
        }
    }
}